GLUE
Monte Rosa Therapeutics, Inc.
$21.98
-1.06 (-4.60%)
At close · Jul 13
Market Cap
$1.86B
Shares
84,479,418
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$21.98
Open$22.69
Day$20.93–23.05
52W$4.12–25.77
Avg vol 30d1.5M
Short int18.6M · 22.1% float · 8.5d
Short vol36%
Last earningsMar 20, 2025
DataJun 2021–Jul 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 17.2 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+28%
above
Price vs 50-day avg
+11%
above
RSI (14)
53
neutral
MACD trend
Negative
52-week position
82%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+29%
trailing
6-month return
−7%
trailing
YTD return
+40%
this year
Relative strength
−16%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $20 › 200d $17 — 50d above 200d
Institutional flow
Distributing
5 of 190 funds reported for Jun 30 · net -5.0K sh shares
Insider flow
Distributing
Net -$825.0K over 90 days · 100% sells
Short interest
Rising
22.06% of float · ▲ +8.5% MoM · 8.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
190 holders — near 3-yr high, broad support
Squeeze score
80
high risk · 0–100
Fundamentals
Revenue growth
+64%
Y/Y
Free cash flow
$-27.5M
Balance sheet
$129.9M
net cash
Quant / Vol
risk profile
Volatility
94%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+28%
Bullish
Price vs 50-day avg
+11%
Bullish
RSI (14)
53
Neutral
MACD trend
Negative
Bearish
52-week position
82%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $20 › 200d $17 — 50d above 200d
Institutional flow
Distributing
5 of 190 funds reported for Jun 30 · net -5.0K sh shares
Insider flow
Distributing
Net -$825.0K over 90 days · 100% sells
Short interest
Rising
22.06% of float · ▲ +8.5% MoM · 8.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
190 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $4
Now $22 · 82%
52-wk high $26
vs 200-day avg +28%
vs 50-day avg +11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GLUE
this stock
Monte Rosa Therapeutics, Inc.
|
$1.86B | +40.2% | — | — | 22.1% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.89B | +5.9% | +46.2% | 28.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.52B | -14.0% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.76B | +4.2% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GLUE | -5.5% | +28.5% | -7.3% | -9.2% | +40.2% |
| SPY | -0.3% | +1.6% | +8.3% | +0.3% | +9.9% |
| vs SPY | -5.2% | +27.0% | -15.6% | -9.5% | +30.3% |